Cargando…

Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy

With the emerging threat of infections caused by multidrug resistant bacteria, phages have been reconsidered as an alternative for treating infections caused by tenacious pathogens. However, instead of replacing antibiotics, the combination of both types of antimicrobials can be superior over the us...

Descripción completa

Detalles Bibliográficos
Autores principales: Tagliaferri, Thaysa Leite, Jansen, Mathias, Horz, Hans-Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387922/
https://www.ncbi.nlm.nih.gov/pubmed/30834237
http://dx.doi.org/10.3389/fcimb.2019.00022
_version_ 1783397662501896192
author Tagliaferri, Thaysa Leite
Jansen, Mathias
Horz, Hans-Peter
author_facet Tagliaferri, Thaysa Leite
Jansen, Mathias
Horz, Hans-Peter
author_sort Tagliaferri, Thaysa Leite
collection PubMed
description With the emerging threat of infections caused by multidrug resistant bacteria, phages have been reconsidered as an alternative for treating infections caused by tenacious pathogens. However, instead of replacing antibiotics, the combination of both types of antimicrobials can be superior over the use of single agents. Enhanced bacterial suppression, more efficient penetration into biofilms, and lowered chances for the emergence of phage resistance are the likely advantages of the combined strategy. While a number of studies have provided experimental evidence in support of this concept, negative interference between phages and antibiotics have been reported as well. Neutral effects have also been observed, but in those cases, combined approaches may still be important for at least hampering the development of resistance. In any case, the choice of phage type and antibiotic as well as their mixing ratios must be given careful consideration when deciding for a dual antibacterial approach. The most frequently tested bacterium for a combined antibacterial treatment has been Pseudomonas aeruginosa, but encouraging results have also been reported for Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Enterococcus faecalis, and Burkholderia cepacia. Given the immense play area of conceivable phage-antibiotic combinations and their potential excess value, it is time to recapitulate of what has been achieved so far. This review therefore gathers and compares the results from most relevant studies in order to help researchers and clinicians in their strategies to combat multidrug resistant bacteria. Special attention is given to the selected bacterial model organisms, the phage families and genera employed, and the experimental design and evaluation (e.g., in vitro vs. in vivo models, biofilm vs. planktonic culture experiments, order and frequency of administration etc.). The presented data may serve as a framework for directed further experimental approaches to ultimately achieve a resolute challenge of multidrug resistant bacteria based on traditional antibiotics and phages.
format Online
Article
Text
id pubmed-6387922
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-63879222019-03-04 Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy Tagliaferri, Thaysa Leite Jansen, Mathias Horz, Hans-Peter Front Cell Infect Microbiol Cellular and Infection Microbiology With the emerging threat of infections caused by multidrug resistant bacteria, phages have been reconsidered as an alternative for treating infections caused by tenacious pathogens. However, instead of replacing antibiotics, the combination of both types of antimicrobials can be superior over the use of single agents. Enhanced bacterial suppression, more efficient penetration into biofilms, and lowered chances for the emergence of phage resistance are the likely advantages of the combined strategy. While a number of studies have provided experimental evidence in support of this concept, negative interference between phages and antibiotics have been reported as well. Neutral effects have also been observed, but in those cases, combined approaches may still be important for at least hampering the development of resistance. In any case, the choice of phage type and antibiotic as well as their mixing ratios must be given careful consideration when deciding for a dual antibacterial approach. The most frequently tested bacterium for a combined antibacterial treatment has been Pseudomonas aeruginosa, but encouraging results have also been reported for Escherichia coli, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Enterococcus faecalis, and Burkholderia cepacia. Given the immense play area of conceivable phage-antibiotic combinations and their potential excess value, it is time to recapitulate of what has been achieved so far. This review therefore gathers and compares the results from most relevant studies in order to help researchers and clinicians in their strategies to combat multidrug resistant bacteria. Special attention is given to the selected bacterial model organisms, the phage families and genera employed, and the experimental design and evaluation (e.g., in vitro vs. in vivo models, biofilm vs. planktonic culture experiments, order and frequency of administration etc.). The presented data may serve as a framework for directed further experimental approaches to ultimately achieve a resolute challenge of multidrug resistant bacteria based on traditional antibiotics and phages. Frontiers Media S.A. 2019-02-18 /pmc/articles/PMC6387922/ /pubmed/30834237 http://dx.doi.org/10.3389/fcimb.2019.00022 Text en Copyright © 2019 Tagliaferri, Jansen and Horz. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Tagliaferri, Thaysa Leite
Jansen, Mathias
Horz, Hans-Peter
Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
title Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
title_full Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
title_fullStr Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
title_full_unstemmed Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
title_short Fighting Pathogenic Bacteria on Two Fronts: Phages and Antibiotics as Combined Strategy
title_sort fighting pathogenic bacteria on two fronts: phages and antibiotics as combined strategy
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6387922/
https://www.ncbi.nlm.nih.gov/pubmed/30834237
http://dx.doi.org/10.3389/fcimb.2019.00022
work_keys_str_mv AT tagliaferrithaysaleite fightingpathogenicbacteriaontwofrontsphagesandantibioticsascombinedstrategy
AT jansenmathias fightingpathogenicbacteriaontwofrontsphagesandantibioticsascombinedstrategy
AT horzhanspeter fightingpathogenicbacteriaontwofrontsphagesandantibioticsascombinedstrategy